The Glycobiology and Malaria Parasite Biology research group, led by Dr Luis Izquierdo at the Barcelona Institute for Global Health (ISGlobal), focuses on the glycobiology of Plasmodium falciparum, the parasite responsible for malaria. The group explores the molecular intricacies of glycan biosynthesis and modifications in P. falciparum to identify new therapeutic, diagnostic, and vaccine opportunities. Glycans, carbohydrate chains ubiquitous on cell surfaces, play critical roles in parasite biology, including survival, virulence, immune evasion, and host-pathogen interactions.
Understanding these processes at a molecular level is pivotal to the group’s mission of disrupting the parasite's life cycle and uncovering innovative targets for antimalarial interventions. Their work delves deeply into the biology of parasite glycosylation, a process central to the modification of proteins and lipids, which shapes the parasite’s ability to survive, infect its host and evade the immune response.
Research Lines
The team’s efforts are structured around three key areas:
- Parasite Glycobiology: Investigating the synthesis and biological function of glycoconjugates, such as glycosylphosphatidylinositol (GPI) anchors, which are critical for protein anchoring and parasite survival. Over 30 GPI-anchored proteins and free GPIs in P. falciparum are essential for virulence and pathogenesis, underscoring the potential of the biosynthetic route as a source of therapeutic targets.
- Drug Target Validation: Identifying and validating enzymes and pathways essential for glycan biosynthesis, such as the Hexosamine Biosynthetic Pathway (HBP). A notable discovery is ApiGNA1, a parasite-specific enzyme with significant differences from its counterpart in humans, making it a promising target for selective antimalarial drugs.
- Immune Responses to Glycans and Their Implications for Vaccine Design: Evaluating the impact of parasite glycans on immune responses and vaccine-related antigens. For instance, glycan modifications may influence protein antigenicity potentially impacting immune recognition. Recent studies also highlight the protective role of anti-α-gal antibodies, which exhibit cytotoxic effects on P. falciparum sporozoites and may hold promise for developing conjugate vaccines targeting malaria.
Current Focus and Impact
The group’s work has described the biosynthesis and roles of glycosylation precursors across various parasite life stages, advancing the understanding of P. falciparum biology. Key findings highlight the critical role of pathways like the HBP and N-glycosylation in the survival of the asexual blood stages of P. falciparum, which are responsible for the clinical symptoms of malaria. Moreover, ongoing research is extending these insights to explore the significance of these pathways in other essential stages of the parasite's complex life cycle, such as the transmission and liver stages, to uncover additional vulnerabilities.
Additionally, the team collaborates nationally and internationally and employs multidisciplinary approaches, combining glycobiology, enzymology, genetics, and immunology. By bridging fundamental research with applied science, they aim to translate their discoveries into practical solutions, such as novel antimalarials, diagnostic tools, and vaccines.
In summary, the group’s pioneering efforts in parasite glycobiology and related processes illuminate critical aspects of P. falciparum biology, driving the development of innovative strategies to combat malaria. Their research could lay the foundation for breakthroughs in addressing one of the world’s most challenging infectious diseases.
With the support of:
Team
ISGlobal Team
GlycoTargets
New antimalarial therapies targeting the glycosylation pathways of ‘Plasmodium falciparum’
This content is related to the following SDGs:
